Baird upgraded Zimmer to "outperform" from "neutral," according to a Rock Hill Daily report.
Baird analysts cited lowered investor expectations for orthopedic end market trends and moderating earnings expectations following its Biomet acquisition. Baird raised its price target to $125 from $110 on Zimmer shares. The stock price is expected to reach $125.80 in the short term.
Zimmer shares sank 4.17 percent during the past week and dropped 0.44 percent in the past month. The 52-week low of the shares is $90.48.
More articles on devices:
K2M sets follow-on offering at $18.75 per share — 5 things to know
Implanet's JAZZ technology receives intellectual patent protection in Europe
FTC makes second request for additional information on Wright Medical-Tornier merger — 5 points